Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: Mapping of CD8+ T Cell Epitopes.

Registros relacionados

• Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
  por: Borthwick, N, et al.
  Publicado em: (2013)
• Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines.
  por: Borthwick, N, et al.
  Publicado em: (2017)
• The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial
  por: Ondondo, B, et al.
  Publicado em: (2013)
• Characterisation of T cells induced by candidate prophylactic vaccines encoding a HIV-1 conserved immunogen in phase I/IIa trial HIVCORE002
  por: Ahmed, T, et al.
  Publicado em: (2011)
• Control of HIV-1 by CD8+T cells specific for epitopes of conserved mosaic vaccine immunogens
  por: Murakoshi, H, et al.
  Publicado em: (2018)